Polymyalgia
rheumatica is an
inflammatory disorder which causes stiffness and aching, and usually affects
adults over the age of 50 years. This disease affects women somewhat more than
men. The cause of polymyalgia rheumatica is unknown.
Access
Detailed Report Summary:
Polymyalgia
rheumatica is related to another inflammatory disorder, giant cell arteritis,
which can cause vision difficulties, scalp tenderness, jaw pain, and headaches.
Pain in shoulders, neck, upper arms, buttocks, hips and thighs; stiffness in
the affected areas; limited range of motion in affected areas; and stiffness in
wrists, elbows and knees are some of the common symptoms of polymyalgia
rheumatica.
Request
to Get Free Sample Pages at:
Involvement
of the upper arms, with trouble raising them above the shoulders is common in
the patients with this disease. Corticosteroids and nonsteroidal
anti-inflammatory drugs (NSAIDs) are common medications for the treatment of
polymyalgia rheumatica. GlaxoSmithKline plc is in the process of developing
sirukumab as an interleukin 6 (IL6) human monoclonal antibody for the treatment
of polymyalgia rheumatica. Other than this Chugai Pharmaceutical Co. Ltd., and
Eli Lilly and Company are also involved in polymyalgia rheumatica pipeline.
Make
Enquiry Before Buying the Report:
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
